NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Bryostatin and Vincristine in B-Cell Malignancies

Phase 1

Completed

Conditions: Recurrent Adult Lymphoblastic Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Multiple Myeloma
Stage III Multiple Myeloma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: bryostatin 1
Drug: vincristine sulfate
Other: laboratory biomarker analysis

First Posted Date: 2004-03-19

Last Posted Date: 2013-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00003166

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: becatecarin

First Posted Date: 2004-03-16

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00005085

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Atlanta Cancer Care, Atlanta, Georgia, United States
🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Phase 1

Completed

Conditions: Lymphoma
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-03-12

Last Posted Date: 2013-03-21

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00003368

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States

and more 42 locations

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: FOLFOX regimen
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2004-03-11

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00016978

Locations: 🇺🇸
CentraCare Clinic, Saint Cloud, Minnesota, United States
🇺🇸
CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
🇺🇸
Rapid City Regional Hospital, Rapid City, South Dakota, United States

and more 21 locations

Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: topotecan hydrochloride
Radiation: radiation therapy

First Posted Date: 2004-03-11

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00002537

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Phase 2

Terminated

Conditions: HER2-positive Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: trastuzumab
Drug: ixabepilone
Other: laboratory biomarker analysis

First Posted Date: 2004-03-10

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00079326

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Ovarian Endometrioid Adenocarcinoma
Ovarian Mixed Epithelial Carcinoma
Primary Peritoneal Cavity Cancer
Stage II Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Fallopian Tube Cancer
Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma

Interventions: Procedure: adjuvant therapy
Drug: paclitaxel
Drug: carboplatin
Biological: bevacizumab

First Posted Date: 2004-03-10

Last Posted Date: 2019-07-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 113

Registration Number: NCT00079430

Locations: 🇯🇵
Kawasaki Medical School, Okayama-Ken, Kurashiki, Japan
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 16 locations

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: temsirolimus
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-03-10

Last Posted Date: 2013-10-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00079456

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Recurrent Adult Acute Myeloid Leukemia
Refractory Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: decitabine
Drug: valproic acid
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-03-10

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT00079378

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

Phase 3

Completed

Conditions: Adenocarcinoma of the Colon
Stage III Colon Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: Locally Directed Therapy
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: fluorouracil
Biological: cetuximab

First Posted Date: 2004-03-10

Last Posted Date: 2020-05-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3397

Registration Number: NCT00079274

Locations: 🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸
Hematology and Oncology Associates, Chicago, Illinois, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 872 locations

Home Terms & Conditions Privacy Policy